Literature DB >> 23440519

Interactions of linoleic and alpha-linolenic acids in the development of fatty acid alterations in cystic fibrosis.

Waddah Katrangi1, Joshua Lawrenz, Adam C Seegmiller, Michael Laposata.   

Abstract

Patients with cystic fibrosis (CF) exhibit characteristic polyunsaturated fatty acid abnormalities, including low linoleic acid and high arachidonic acid levels that are thought to contribute to the pathophysiology of this disease. Recent studies indicate that changes in fatty acid metabolism are responsible for these abnormalities. This study examines the role of fatty acid substrate concentrations in the development of these alterations in a cultured cell model of CF. By incubating cells with varying concentrations of exogenous fatty acids, it shows that increasing the concentration of substrates from the parallel n-3 and n-6 polyunsaturated fatty acid pathways (linoleic acid and alpha-linolenic acid, respectively) not only increases formation of the products in that pathway, but also reduces metabolism in the parallel pathway. In particular, we demonstrate that high levels of linoleic acid and low levels of alpha-linolenic acid are required to observe the typical fatty acid alterations of cystic fibrosis. These results shed light on the mechanisms of fatty acid metabolic abnormalities in cystic fibrosis. They also have implications for the nutritional therapy of CF, highlighting the importance of specific fatty acid content, and in understanding the anti-inflammatory effects of n-3 fatty acids.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23440519     DOI: 10.1007/s11745-013-3768-4

Source DB:  PubMed          Journal:  Lipids        ISSN: 0024-4201            Impact factor:   1.880


  34 in total

1.  Total fat intake modifies plasma fatty acid composition in humans.

Authors:  S K Raatz; D Bibus; W Thomas; P Kris-Etherton
Journal:  J Nutr       Date:  2001-02       Impact factor: 4.798

2.  A membrane lipid imbalance plays a role in the phenotypic expression of cystic fibrosis in cftr(-/-) mice.

Authors:  S D Freedman; M H Katz; E M Parker; M Laposata; M Y Urman; J G Alvarez
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

3.  A fat lot of good: balance and trends in fat intake in children with cystic fibrosis.

Authors:  C Smith; A Winn; P Seddon; S Ranganathan
Journal:  J Cyst Fibros       Date:  2011-11-25       Impact factor: 5.482

4.  Changes in consumption of omega-3 and omega-6 fatty acids in the United States during the 20th century.

Authors:  Tanya L Blasbalg; Joseph R Hibbeln; Christopher E Ramsden; Sharon F Majchrzak; Robert R Rawlings
Journal:  Am J Clin Nutr       Date:  2011-03-02       Impact factor: 7.045

5.  Increased elongase 6 and Δ9-desaturase activity are associated with n-7 and n-9 fatty acid changes in cystic fibrosis.

Authors:  Kelly F Thomsen; Michael Laposata; Sarah W Njoroge; Obi C Umunakwe; Waddah Katrangi; Adam C Seegmiller
Journal:  Lipids       Date:  2011-05-05       Impact factor: 1.880

6.  DHA and EPA reverse cystic fibrosis-related FA abnormalities by suppressing FA desaturase expression and activity.

Authors:  Sarah W Njoroge; Michael Laposata; Waddah Katrangi; Adam C Seegmiller
Journal:  J Lipid Res       Date:  2011-11-16       Impact factor: 5.922

Review 7.  Essential fatty acid synthesis and its regulation in mammals.

Authors:  M T Nakamura; T Y Nara
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2003-02       Impact factor: 4.006

8.  Cystic fibrosis fatty acid imbalance is linked to ceramide deficiency and corrected by fenretinide.

Authors:  Claudine Guilbault; Gabriella Wojewodka; Zienab Saeed; Marian Hajduch; Elias Matouk; Juan B De Sanctis; Danuta Radzioch
Journal:  Am J Respir Cell Mol Biol       Date:  2008-12-04       Impact factor: 6.914

9.  Association of cystic fibrosis with abnormalities in fatty acid metabolism.

Authors:  Steven D Freedman; Paola G Blanco; Munir M Zaman; Julie C Shea; Mario Ollero; Isabel K Hopper; Deborah A Weed; Andres Gelrud; Meredith M Regan; Michael Laposata; Juan G Alvarez; Brian P O'Sullivan
Journal:  N Engl J Med       Date:  2004-02-05       Impact factor: 91.245

10.  Increased tissue arachidonic acid and reduced linoleic acid in a mouse model of cystic fibrosis are reversed by supplemental glycerophospholipids enriched in docosahexaenoic acid.

Authors:  Myriam Mimoun; Thierry C Coste; Jean Lebacq; Patrick Lebecque; Pierre Wallemacq; Teresinha Leal; Martine Armand
Journal:  J Nutr       Date:  2009-10-14       Impact factor: 4.798

View more
  4 in total

1.  Abnormal n-6 fatty acid metabolism in cystic fibrosis is caused by activation of AMP-activated protein kinase.

Authors:  Obi C Umunakwe; Adam C Seegmiller
Journal:  J Lipid Res       Date:  2014-05-24       Impact factor: 5.922

Review 2.  Pathophysiology of cystic fibrosis and drugs used in associated digestive tract diseases.

Authors:  Adriana Haack; Giselle Gonçalves Aragão; Maria Rita Carvalho Garbi Novaes
Journal:  World J Gastroenterol       Date:  2013-12-14       Impact factor: 5.742

3.  A Network Pharmacology Approach to Explore the Mechanisms of Shugan Jianpi Formula in Liver Fibrosis.

Authors:  Chang Fan; Fu Rong Wu; Jia Fu Zhang; Hui Jiang
Journal:  Evid Based Complement Alternat Med       Date:  2020-06-12       Impact factor: 2.629

Review 4.  Abnormal unsaturated fatty acid metabolism in cystic fibrosis: biochemical mechanisms and clinical implications.

Authors:  Adam C Seegmiller
Journal:  Int J Mol Sci       Date:  2014-09-11       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.